Eluxadoline

Revision as of 14:06, 23 January 2017 by Martin Nino (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{MN}} |genericName=Eluxadoline |aOrAn=a |drugClass=mu-opioid receptor agonist |indicationType=treatment |indication=adults with irritab...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Eluxadoline
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Martin Nino [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Eluxadoline is a mu-opioid receptor agonist that is FDA approved for the treatment of adults with irritable bowel syndrome with diarrhea (IBS-D).. Common adverse reactions include constipation, nausea and abdominal pain (>5%)..

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

Eluxadoline is indicated in adults for the treatment of irritable bowel syndrome with diarrhea (IBS-D).

Dosage

The recommended dosage of Eluxadoline is 100 mg taken orally twice daily with food.

The recommended dosage of Eluxadoline is 75 mg taken orally twice daily with food in patients who:

  • do not have a gallbladder.
  • are unable to tolerate the 100 mg dose of Eluxadoline.
  • are receiving concomitant OATP1B1 inhibitors.
  • have mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment.

Discontinue Eluxadoline in patients who develop severe constipation for more than 4 days.

Instruct patients if they miss a dose, take the next dose at the regular time and not to take 2 doses at the same time to make up for a missed dose.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Eluxadoline in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Eluxadoline in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

Safety and effectiveness in pediatric patients have not been established.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Eluxadoline in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Eluxadoline in pediatric patients.

Contraindications

There is limited information regarding Eluxadoline Contraindications in the drug label.

Warnings

There is limited information regarding Eluxadoline Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Eluxadoline Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Eluxadoline Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Eluxadoline Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Eluxadoline in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Eluxadoline in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Eluxadoline during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Eluxadoline in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Eluxadoline in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Eluxadoline in geriatric settings.

Gender

There is no FDA guidance on the use of Eluxadoline with respect to specific gender populations.

Race

There is no FDA guidance on the use of Eluxadoline with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Eluxadoline in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Eluxadoline in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Eluxadoline in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Eluxadoline in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Eluxadoline Administration in the drug label.

Monitoring

There is limited information regarding Eluxadoline Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Eluxadoline and IV administrations.

Overdosage

There is limited information regarding Eluxadoline overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Eluxadoline Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Eluxadoline Mechanism of Action in the drug label.

Structure

There is limited information regarding Eluxadoline Structure in the drug label.

Pharmacodynamics

There is limited information regarding Eluxadoline Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Eluxadoline Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Eluxadoline Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Eluxadoline Clinical Studies in the drug label.

How Supplied

There is limited information regarding Eluxadoline How Supplied in the drug label.

Storage

There is limited information regarding Eluxadoline Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Eluxadoline |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Eluxadoline |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Eluxadoline Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Eluxadoline interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Eluxadoline Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Eluxadoline Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.